Jason Haas - Oct 6, 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Financial Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Oct 6, 2022
Transactions value $
$0
Form type
4
Date filed
10/11/2022, 04:37 PM
Previous filing
Jun 29, 2022
Next filing
Feb 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +49.8K $0.00 49.8K Oct 6, 2022 Common Stock 49.8K $6.73 Direct F1
transaction SYRS Restricted Stock Units Award $0 +37.8K $0.00 37.8K Oct 6, 2022 Common Stock 37.8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Remarks:

Exhibit 24: Power of Attorney